Cambria Cannabis ETF
TOKE
Chicago Board Options Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 3300 Highland Avenue Manhattan Beach CA United States of America 90266
- IPO Date
- Jul 25, 2019
- CIK
- 0001529390
- Website
- cambriafunds.com
- Similar Companies
- Business
- Cambria Cannabis ETF (TOKE) is an actively managed exchange-traded fund that seeks capital appreciation through investments in global equity securities with exposure to the broad cannabis and hemp industry, targeting approximately 20 to 50 top companies across all market capitalizations worldwide. The ETF holds a diversified portfolio of 35 holdings, including companies involved in cannabis cultivation, production, distribution, biotechnology, pharmaceuticals, real estate, food, medicine, and related sectors such as health care, consumer discretionary, and consumer staples; it provides investors with low-cost, non-leveraged access to this thematic sector via quarterly dividends and a net expense ratio of 0.43% after waivers in effect until August 31, 2025. Issued by Cambria ETF Trust and managed by Cambria Investment Management, LP, with portfolio managers Mebane T. Faber and Jonathan Keetz, TOKE trades on Cboe BZX under the ticker TOKE (CUSIP 132061821) and focuses on firms benefiting from structural growth in cannabis-related markets despite regulatory risks from varying local and federal laws, including U.S. federal prohibitions on marijuana. Launched on July 25, 2019, and headquartered in Los Angeles, California, the fund operates globally with assets under management of approximately $14.26 million as of recent data, distributed by ALPS Distributors, Inc. In recent developments, TOKE experienced significant market volatility, including double-digit gains in December 2025 amid speculation on U.S. cannabis reform under President Trump, alongside ongoing fee waivers extended through mid-2025 and sustained active management adjustments to its holdings amid industry consolidation.